H.C. Wainwright analyst Swayampakula Ramakanth raised the firm’s price target on Delcath Systems to $18 from $17 and keeps a Buy rating on the shares after the company announced FDA approval of its Hepzato Kit in adult patients with metastatic uveal melanoma with unresectable hepatic metastases. The firm projects Hepzato to generate revenues of nearly $276M in the U.S. by 2032. It also believes Delcath has sufficient funds to run operations “for the foreseeable future.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on DCTH:
- Unusually active option classes on open August 15th
- Delcath Systems (NASDAQ:DCTH) Skyrockets on FDA Approval for Hepzato Liver Therapy
- Delcath Systems price target raised to $18 from $14 at Canaccord
- Delcath Systems announces FDA approval of Hepzato KIT
- Delcath Systems announces FDA approval of HEPZATO KIT in mUM
